Table 3 Parameters of glucose metabolism, lipid metabolism, and inflammation in patients without (AdipoR2) and with the adiponectin receptor 2 SNP cluster (AdipoR2-SNP) after 12 weeks of placebo or telmisartan treatment. Data are presented as median and interquartile range.
Placebo treatment | Telmisartan treatment | |||||
|---|---|---|---|---|---|---|
AdipoR2 | AdipoR2-SNP | p | AdipoR2 | AdipoR2-SNP | p | |
Fasting plasma glucose [mg/dl] | 100 (94–105) | 103 (100–114) | 0.44 | 99 (94–107) | 103 (97–114) | 0.53 |
Fasting insulin [μU/ml] * | 11.5 (10.0–20.6) | 16.7 (8.1–36.8) | 0.55 | 11.9 (7.6–17.7) | 14.0 (7.8–20.0) | 0.61 |
Fasting C-peptide [ng/ml] | 2.50 (2.20–2.90) | 3.30 (1.90–4.45) | 0.55 | 2.50 (2.20–3.10) | 2.70 (1.60–3.35) | 0.80 |
1st phase insulin secretion [pmol/l] * | 554 (346–882) | 536 (308–814) | 1.00 | 519 (359–698) | 565 (452–820) | 0.61 |
2nd phase insulin secretion [pmol/l] * | 176 (135–246) | 171 (125–235) | 0.93 | 164 (131–207) | 185 (151–238) | 0.61 |
Glucose iAUC iv GTT [mg*min/dl]† | 1753 (1507–1905) | 1818 (1555–3497) | 0.47 | 1600 (1163–1866) | 1510 (1326–1914) | 0.80 |
Glucose iAUC oral GTT [mg*h/dl] * | 90 (59–111) | 79 (74–104) | 1.00 | 86 (48–105) | 67 (31–106) | 0.50 |
Insulin iAUC iv GTT [μU*min/ml]† | 388 (278–1137) | 633 (227–1119) | 0.82 | 407 (297–591) | 827 (359–1004) | 0.35 |
Insulin iAUC oral GTT [μU*h/ml] * | 110 (71–198) | 74 (64–105) | 0.27 | 128 (60–164) | 65 (50–156) | 0.44 |
Insulin sensitivity index * | -0.07 (-0.25–0.02) | -0.04 (-0.26–0.07) | 0.50 | -0.05 (-0.28–0.07) | 0.02 (-0.25–0.05) | 1.00 |
Insulin sensitivity index composite * | 2.81 (2.20–4.28) | 2.61 (2.10–5.67) | 0.93 | 2.60 (1.84–4.79) | 2.62 (2.47–4.66) | 0.82 |
HOMA-index | 2.95 (2.56–4.77) | 4.28 (2.01–10.0) | 0.50 | 2.87 (1.74–4.40) | 3.52 (1.90–5.67) | 0.50 |
HbA1c [%] | 5.50 (5.20–5.50) | 5.40 (5.25–5.65) | 0.93 | 5.35 (5.30–5.65) | 5.30 (5.30–5.70) | 0.82 |
Fasting total cholesterol [mg/dl] | 189 (160–224) | 177 (146–209) | 0.61 | 182 (164–222) | 176 (140–204) | 0.67 |
Fasting HDL-cholesterol [mg/dl] | 48 (36–58) | 52 (43–60) | 0.61 | 43 (38–56) | 49 (44–60) | 0.35 |
Fasting LDL-cholesterol [mg/dl] | 100 (81–137) | 114 (76–137) | 0.93 | 96 (73–125) | 114 (73–137) | 0.61 |
Fasting TG [mg/dl] | 162 (123–287) | 79 (64–132) | 0.01 | 193 (144–302) | 105 (79–113) | <0.01 |
Fasting VLDL-TG [mg/dl] | 108 (56–208) | 51 (34–91) | 0.07 | 126 (68–228) | 59 (38–79) | 0.03 |
Fasting VLDL-cholesterol [mg/dl] | 29 (18–42) | 8 (8–25) | 0.06 | 32 (15–49) | 11 (8–16) | 0.03 |
TG iAUC fat tolerance [mg*h/dl] ‡ | 772 (342–1501) | 519 (383–1294) | 0.75 | 931 (438–1380) | 632 (343–1142) | 0.50 |
VLDL-TG iAUC fat tolerance [mg*h/dl] ‡ | 293 (236–611) | 238 (87–637) | 0.44 | 317 (149–580) | 371 (199–376) | 0.75 |
Chyl-TG iAUC fat tolerance [mg*h/dl] ‡ | 529 (301–943) | 402 (313–756) | 0.96 | 639 (313–1164) | 589 (184–764) | 0.39 |
Adiponectin [ng/ml] | 2008 (1425–2413) | 3822 (2944–4553) | 0.02 | 2014 (1465–2574) | 4573 (2912–4787) | 0.04 |
High sensitivity CRP [mg/l] | 6.23 (2.26–8.06) | 2.50 (1.54–4.19) | 0.10 | 6.12 (2.85–9.85) | 2.25 (1.38–4.81) | 0.07 |
Interleukin-6 [pg/ml] | 1.44 (1.11–2.20) | 1.17 (0.77–2.11) | 0.55 | 1.46 (1.24–2.52) | 1.35 (1.03–2.39) | 0.93 |
Fibrinogen [mg/dl] | 418 (366–479) | 410 (330–470) | 0.61 | 415 (375–477) | 401 (352–475) | 0.67 |